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Carbonic anhydrase family (CAs) plays an important role in the extracellular acidification and several studies suggest a possible
involvement of such enzymes in the increased tumor progression due to the acidic extracellular pH. We measured the activities of carbonic
anhydrase I and II isoforms in a group of patients affected by four specific chronic haematological diseases, sharing a common origin but
characterized by a different neoplastic evolution: agnogenic myeloid metaplasia (AMM), essential thrombocythemia (ET), chronic myeloid
leukemia (CML) and polycythemia vera (PV) in order to understand the correlation between CAs activities and neoplastic outcome. In
comparison to controls, our data demonstrate an increase of CAI and CAII activities in all our patients with a specific increase of the CAI
activity in the group of the diseases with major malignancy (CML and AMM). These results suggest a possible role of such isozymes in the
progression of the myeloid disorders and CAs specific inhibitors should be useful in slowing the progression of the disease.
D 2004 Elsevier B.V. All rights reserved.Keywords: Carbonic anhydrase; Myeloid; PhenotypeAcidification of extracellular milieu in malignant
tumors is reported to increase the invasive behaviour of
cancer cells [1]. Several studies suggest a possible role for
carbonic anhydrase isozymes that catalyze the reversible
hydration of CO2 to H2CO3 [2]. To generate the pH
gradient between the extracellular and intracellular com-
partments, tumor cells express ion transport proteins
including vacuolar H+-ATPase, Cl/HCO3
 exchanger
and Na+/H+ exchanger and carbonic anhydrases to cata-
lyze the production of H+ and HCO3
+ [3]. At present, 13
enzymatically active CA isoenzymes were identified from
mammals, namely cytosolic CAI, II III and VII, mito-
chondrial CA VA and VB, secretory CA VI, and mem-
brane-associated CA IV, IX, XII and XIV. Recently a
novel member of the CAs family, with high structural
similarity to cytosolic isoenzymes, named CA XIII, was
identified [4]. CAI is present into the erythrocytes, it is a
low activity CA, and its biological role is not well0925-4439/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
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widest cytosolic distribution of the carbonic anhydrases
[5]. Mutations in CAII gene result in an inherited disease
[6]. The expression of CAI and CAII isozymes has been
also investigated in several neoplastic and haematological
diseases [7]. Immunological studies indicate that the
carbonic anhydrases could have a role in tumors, includ-
ing malignant brain tumors [8] and gastric and pancreatic
carcinomas [9]. CAI is abundantly expressed both in the
early neoplastic erythroblast in vitro and in human eryth-
roleukemias in vivo [10], and recently has been demon-
strated that there is a specific CA II increased expression
in the blast cells of acute myeloid leukemia, acute
lymphoblastic leukemia and chronic myelomonocytic leu-
kemia not respective of the cell lineage [11]. Despite these
studies, there are few data on the activity of CAI and
CAII isoenzymes in chronic myeloid disorders (CMDs),
another group of haematological diseases characterized by
a slow progression, often towards a leukemic condition.
We therefore decided to measure the CAI and II activities
in four different myeloproliferative disorders characterized
by a different progressive worst clinical phenotype, in
order to evaluate a possible CAI and CAII involvement in
Fig. 1. Red blood cell total carbonic anhydrase (CAI +CAII) (A), specific
CAI (B) and CAII activities (C) in patients affected by polycythemia vera
(PV), essential thrombocythemia (ET), chronic myeloid leukemia (CML),
and agnogenic myeloid metaplasia (AMM). Total CA activities, CAII and
CAI activities were significantly elevated in all of four groups of chronic
myeloid patients.
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samples were obtained from 30 healthy donors (HD) (18–
65 years old). The patients were 14 (36–79 years) with
essential thrombocythemia (ET), 8 (49–72 years) with
chronic myeloid leukemia (CML), 15 (38–70 years) with
agnogenic myeloid metaplasia (AMM), 7 (35–68 years)
with polycythemia vera (PV). In all of patients the diagnosis
was made according to the standard criteria for CMPD [12].
The patients were enrolled at the diagnosis before starting
the therapy and were well matching for blast count, bone
marrow cellularity, bone marrow fibrosis, disease’s grade
and routine haematological parameters. Only the patients
with Hb values above 10 gr/dl, not transfused, were
included in the study. Blood specimens were collected by
venipuncture in heparinized test tubes. Leukocytes were
isolated by lymphoprep density gradient centrifugation,
washed twice with cold PBS and sonicated in solubilization
buffer 0.1 M Tris SO4 pH 7.5 containing 1 mM Benzami-
dine, 1 mM o-phenatroline. The pellet from lymphoprep
(red cells) was collected, diluted 1:100 with bidistilled
water and then stored at  20 jC until the haemoglobin
and CAs were assayed. For the evaluation of Hb levels a
spectrophotometric assay was used as described. Briefly,
0.2 ml of 1:100 diluted blood was added to 0.8 ml of
ammonium hydroxide solution 0.006 N. The optical density
at 576 nm (OD 576) was red on a Beckmann DU 60
spectrophotometer using as blank 0.2 ml of bidistilled
water. The haemoglobin levels (mg/ml) were calculated
by the formulae: mg Hb/ml =OD576 500/0.912. The total
CA activity (CAI plus CAII) was evaluated according to the
procedure of Maren [13] as described [14]. The CAII
activity was determined in presence of sodium iodide, a
CAI-specific inhibitor. The CAI activity was calculated as
difference between total CA and CAII activities. The results
were expressed in units of CA per milligram of Hb
(Haemoglobin) for the red cells and in units of CA per
milligram of total proteins for leukocytes. The protein
concentration was determined by Lowry procedure using
bovine serum albumin as a standard. A Kruskall–Wallis test
was used to determine whether the red blood cells CAtot
and CAI activities of CMPDs patients were significantly
different versus normal controls. A Mann–Witney test was
used to evaluate significant differences in CAII leukocytes
activity of CMDs patients. Fig. 1A and B summarizes the
CAtot (CAI +CAII) and CAI activities in the red blood
cells from PV, ET, CML and AMM patients. All patients
(44/44) showed a high activity versus normal control. The
fold increase in CAtot activity varies among different
groups of patients. The highest increase is for AMM
patients (56 F 21 U/mg Hb) fol lowed by CML
(41.13F 17 U/mg Hb), ET (36F 10 U/mg Hb) and PV
patients (27F 13 U/mg Hb). Normal controls (22.3F 3.6 U/
mg Hb). (P< 0.0001 Kruskall–Wallis). The same situation
was observed for CAI values which are more elevated in
AMMpatients (32F 0.4 U/mgHb), followed by CML (26F
U/mg Hb) and ET and PT patients with 21F 8 and 15F 2 U/mg Hb, respectively; normal controls, 12.5F 4 U/mg Hb
(P < 0.0001 Kruskall–Wallis). Fig. 1C summarizes the data
for CAII activity in the same samples. The highest activity is
present in AMM patients (24.2F 4 U/mg Hb) with CML
(15.46F 6 U/mg Hb), ET (15.3F 3 U/mg Hb) and PV
patients (12.4F 7 U/mg Hb); normal controls, 9.8F 3 U/
mg Hb (P< 0.0001 Kruskall–Wallis). However, the fold
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in separated leukocytes were only significantly increased in
CML and AMM patients in comparison to normal control;
CML (20F 3 U/mg of total proteins), AMM (15.2F 1.3
U/mg of total protein), normal control (9.5F 0.8 U/mg
of total protein) (P < 0.001 Mann–Witney). No CAI activ-
ity was present in the leukocytes lysate. The chronic mye-
loproliferative neoplasias are clonal stem cell disorders
caused by the transformation of an undifferentiated hema-
topoietic stem cell. Typically such disorders are classified
in four different groups that recognize a common etiology
but with different clinical outcome. The worst outcome is
displayed by CML that frequently tends to evolve in acute
leukemia and by AMM where the clonal myeloprolifera-
tion is characteristically accompanied by reactive myelofi-
brosis and extramedullary hematopoiesis. The median
survival is estimated to be between 3 and 6 years and
the causes of death include leukemic evolution. The other
two groups include ET and PV that have a milder outcome
and with a median survival higher than 10 years [12].
According with the leukemic evolution of the two worst
outcome CMDs, and with the well-documented overex-
pression of CAs in course of several acute leukemias, we
evaluated the possible contribution of the CAI and CAII
isoforms in course of myeloproliferative disorders with
different clinical phenotype. Our data, show: (i) a signif-
icant increase of total CA (CAI plus CAII), CAI and CAII
specific activities in the red blood cells of all of four types
of chronic myeloproliferative disorders versus normal con-
trols, with the highest increase in the group of AMM and
CML patients with the more unfavourable prognosis. (ii) a
fold CAII elevation lesser then CAI, suggesting a possible
major contribution of CA I isoenzyme in the total red
blood cell CA activity in the course of CMDs. As
expected, the leukocyte CA activity was related only to
the CAII isoform, according to the previous published
immunohistochemical data (Leppilampi M., 2002), and
was significantly increased only in the CML and AMM
patients. Although a study with a larger number of patients
is necessary, our observations, suggesting a possible role
for CAI and CAII isozymes in CML and AMM diseases,
could be relevant for the diagnosis, and follow-up, as well
as for the management of the patients since, as well
described for other neoplasias [15,16], also in these hae-
matological disorders the CA inhibitors may be useful to
control the progression of the disease.Acknowledgements
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